SCHEMBL6772835

SCHEMBL6772835

CCOc1cc(OCC)cc(C(N)CC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
KMT2A Q03164 1/20 0.50
PTGS2 P35354 2/20 0.47
F10 P00742 2/20 0.44
F7 P08709 2/20 0.44
F3 P13726 2/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
FFAR1 O14842 2/20 0.40
PARP10 Q53GL7 1/20 0.39
CTSA P10619 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7337475 0.84 PTGS2 (0.41) SMN1; SMN2KMT2APTGS2F10F7
SCHEMBL5720967 0.83 ALDH1A1 (0.51) SMN1; SMN2KMT2AALDH1A1POLBCYP2C9
SCHEMBL5720965 0.83 ALDH1A1 (0.51) SMN1; SMN2KMT2AALDH1A1POLBCYP2C9
SCHEMBL6432788 0.83 SMN1; SMN2 (0.45) SMN1; SMN2KMT2APTGS2ALDH1A1POLB
SCHEMBL6432790 0.83 SMN1; SMN2 (0.45) SMN1; SMN2KMT2APTGS2ALDH1A1POLB
SCHEMBL12463680 0.83 KMT2A (0.49) SMN1; SMN2KMT2AALDH1A1POLBFFAR1
SCHEMBL5150743 0.83 KMT2A (0.49) SMN1; SMN2KMT2AALDH1A1POLBFFAR1
SCHEMBL12463606 0.83 KMT2A (0.49) SMN1; SMN2KMT2AALDH1A1POLBFFAR1
Hydrochloric Acid SCHEMBL7339305 0.83 PTGS2 (0.40) SMN1; SMN2KMT2APTGS2F10F7
SCHEMBL6693234 0.76 PDE4A (0.50) SMN1; SMN2KMT2AF10F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed